Risk of secondary cases of C. difficile in households doesn't justify interventions
April 5th 2012The risk of Clostridium difficile infection among households is too low to justify interventions, other than avoiding unnecessary antimicrobials, according to a new study, published in April?s Journal of Infection.
Rituximab may be better second-line RA therapy when anti-TNF fails
April 5th 2012Switching patients with rheumatoid arthritis to rituximab (Rituxan, Genentech) may be more effective than switching them to a second alternative anti-tumor necrosis factor (anti-TNF) after a first anti-TNF therapy has failed, according to a study published online in Arthritis Care & Research.
Pharmacists, FTC debate during hearing on anti-trust immunity
April 3rd 2012Should independent pharmacies be given anti-trust immunity to act against contracts presented by pharmacy benefit managers? A representative of the Federal Trade Commission said ?no? and pharmacists said ?yes? during a Congressional subcommittee hearing on HR 1946 last week.